Cell and gene therapies have the potential to transform the lives of patients and their families. As judged by patients' perspectives and experiences, how close are we to realizing this potential? By what approaches can government and drug developers work with patient communities to solve the challenges that remain? In this session, experts will discuss the most pressing pain points and opportunities for the future of cell and gene therapy research, development, and access.

Moderator

Alasdair Milton
Managing Director, Healthcare and Life Sciences Strategy, KPMG

Speakers

Peter Marks
Director, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA)

Andrew Obenshain
CEO, bluebird bio

Mary Schroth
Chief Medical Officer, Cure SMA

Kevin Wake
President, Uriel Owens Sickle Cell Disease Association of the Midwest